{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360021392644898560.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.26226/m.63185c4d7e215f5e7f3850b5"}}],"dc:title":[{"@value":"Long-term improvements in disease severity, itch, and QoL after 3 years of tralokinumab treatment in adults with moderate-to-severe AD"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380021392644898564","@type":"Researcher","foaf:name":[{"@value":"Richard Langley"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898562","@type":"Researcher","foaf:name":[{"@value":"Kristian Reich"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898561","@type":"Researcher","foaf:name":[{"@value":"Eric Simpson"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898565","@type":"Researcher","foaf:name":[{"@value":"Richard Warren"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898560","@type":"Researcher","foaf:name":[{"@value":"Antonio Costanzo"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898571","@type":"Researcher","foaf:name":[{"@value":"Hidehisa Saeki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898569","@type":"Researcher","foaf:name":[{"@value":"Stine Fangel"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898573","@type":"Researcher","foaf:name":[{"@value":"Nathan Lassota"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898563","@type":"Researcher","foaf:name":[{"@value":"Anna Carlsson"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898567","@type":"Researcher","foaf:name":[{"@value":"Martina Fähndrich"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898568","@type":"Researcher","foaf:name":[{"@value":"Melinda Gooderham"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898572","@type":"Researcher","foaf:name":[{"@value":"Jean Philippe"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898570","@type":"Researcher","foaf:name":[{"@value":"Juan Francisco"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898574","@type":"Researcher","foaf:name":[{"@value":"Andreas Pinter"}]},{"@id":"https://cir.nii.ac.jp/crid/1380021392644898566","@type":"Researcher","foaf:name":[{"@value":"Andrew Blauvelt"}]}],"publication":{"dc:publisher":[{"@value":"Morressier GmbH"}],"prism:publicationDate":"2022-10-21"},"reviewed":"false","createdAt":"2022-10-21","modifiedAt":"2024-01-26","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360021390757741568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension <scp>JADE EXTEND</scp> study"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.26226/m.63185c4d7e215f5e7f3850b5"},{"@type":"CROSSREF","@value":"10.1111/jdv.19254_references_DOI_FoDzNYs8fjaqZg7HihvTBwho1YW"}]}